BCIQ Profiles

Company Profile Report
BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.

CRISPR-Cas13a targeting of viral genes for COVID-19, flu

Feb 23, 2021 | 10:42 PM GMT

DISEASE CATEGORY: Infectious disease

INDICATION: Coronavirus; influenza

CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could treat COVID-19 or flu, respectively. In monkey kidney cells infected with SARS-CoV-2, Cas13a targeting of the nucleocapsid reduced cell death by over 72%. Nebulized delivery of Cas13a mRNA plus crRNA against the SARS-CoV-2 nucleocapsid, formulated with a poly(β-amino ester)-based (PBAE) polymer, decreased disease-associated weight loss and lowered lung viral load by 57% in a Syrian hamster model of COVID-19. In mice infected with three times the lethal dose of influenza A virus, nebulized delivery of PBAE-formulated Cas13a mRNA plus crRNA against the PB1 subunit of the virus’ RNA polymerase reduced viral RNA levels in the lungs by 89.1%. Next steps include optimizing the formulation and testing it in large animal models.

TARGET/MARKER/PATHWAY: CRISPR-associated protein 13a (Cas13a; C2c2); SARS-CoV-2 nucleocapsid protein (SARS-CoV-2 N); viral RNA polymerase PB1 subunit; viral RNA polymerase PB2 subunit

EXPERIMENTAL SYSTEM: Cell culture; mice; hamsters

LICENSING STATUS: Patent applications filed; licensing status undisclosed

PUBLICATION DETAILS: Blanchard, E. et al. Nat. Biotechnol.; published online Feb. 3, 2021


CONTACT: Chiara Zurla, Georgia Institute of Technology and Emory University, Atlanta, Ga.

email: chiara@gatech.edu

CONTACT: Philip J. Santangelo, same affiliation as above

email: philip.santangelo@bme.gatech.edu

How to gain access

Continue reading with a
two-week free trial.